Nope Filed last night. Your 20 cent assertion is so ridiculous it's laughable why would the insiders give away their company.
WPCS to 10
Its real simple:
1) 20 million fully diluted shares OS after deal.
2) Current $30 MM valuation is INSANELY CHEAP compared to others in sector.
3) The price drop today was just holders of te convertible notes shorting to lock in profit. They can cover with the converted shares. When this is finished WPCS WILL SKYROCKET.
WPCS $5 soon
Despite the significant relative gain in recent weeks, DSS is still extremely undervalued. Particularly now that the Apple infringement lawsuit has been filed. Before this latest lawsuit, and the progress made in the last quarter in all facets of the business, the only analyst covering the stock had a $4target for DSS. His target was based on assigning a value of $1.65 to the core business, and adding a "conservative" $2.65 to account for the potential revenues from setting the existing patent-infringement lawsuits (against Facebook, LinkedIn, and the ones already settled (Broadvision (BVSN), Jive Software (JIVE), and Novell (NOVL)). The original research and the subsequent update are several months old. An updated research note would likely assign a higher target value. We should know soon if this will be the case or not.
As a reminder, the U.S. District Court for the Northern District of California has set the Markman hearing date for February 26, 2014 for Bascom Research, Inc. vs. Facebook, Inc., and LinkedIn, Corp.
Because of the Facebook and LinkedIn notoriety, not much has been said about DSS stake in VirtualAgility. VirtualAgility provides a user-configurable platform that allows persons who are not specialists in information technology (IT) to create sophisticated, integrated applications. In 2013, VirtualAgility filed patent infringement lawsuits against nine defendants lawsuits.
It is clear that DSS has many patent-infringement lawsuits against large Fortune 500 companies at various stages of development. There are also significant catalysts just a few weeks away from now.
My first article on DSS triggered several questions and comments from my readers about the likely success or failure of DSS' patent-infringement cases. I am not going to address all those questions here, but a frequent comments was "there is no way that DSS will get anything from Facebook - it's like David fighting Goliath." Well, I feel more strongly than ever that DSS has a very go
-Trading near cash value
-Small tightly held 20 MM float
-Red hot biotech market
-Huge volume and bid sizes
-Next painkilling drug works much better, market valung pipeline at 0.
See ya at $2 by Christmas.
Might be worth a nibble.